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Abstract
Fibroblast growth factor 15 (Fgf15) is the mouse orthologue of human FGF19. Fgf15 is highly expressed in the ileum and
functions as an endocrine signal to regulate liver function, including bile acid synthesis, hepatocyte proliferation and insulin
sensitivity. In order to fully understand the function of Fgf15, methods are needed to produce pure Fgf15 protein in the
prokaryotic system. However, when expressed in Escherichia coli (E. coli), the recombinant Fgf15 protein was insoluble and
found only in inclusion bodies. In the current study, we report a method to produce recombinant Fgf15 protein in E. coli
through the use of small ubiquitin-related modifier (SUMO) fusion tag. Even though the SUMO has been shown to strongly
improve protein solubility and expression levels, our studies suggest that the SUMO does not improve Fgf15 protein
solubility. Instead, proper refolding of Fgf15 protein was achieved when Fgf15 was expressed as a partner protein of the
fusion tag SUMO, followed by in vitro dialysis refolding. After refolding, the N-terminal SUMO tag was cleaved from the
recombinant Fgf15 fusion protein by ScUlp1 (Ubiquitin-Like Protein-Specific Protease 1 from S. cerevisiae). With or without
the SUMO tag, the refolded Fgf15 protein was biologically active, as revealed by its ability to reduce hepatic Cyp7a1 mRNA
levels in mice. In addition, recombinant Fgf15 protein suppressed Cyp7a1 mRNA levels in a dose-dependent manner. In
summary, we have developed a successful method to express functional Fgf15 protein in prokaryotic cells.
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Introduction
Fibroblast growth factor 15 (Fgf15) is mainly expressed in
mouse ileum and colon and is not expressed in liver. Its human
homologue is FGF19. Fgf15 contains 218 amino acids (aa),
including a predicted 25-aa signal peptide and a 193-aa secreted
mature protein [1], and shares 50% aa sequence similarity with
FGF19. Fgf15 functions as an enterohepatic hormone in that it is
produced in the small intestine, but travels to the liver via portal
circulation, and then binds to its receptor, FGFR4 that is
expressed in hepatocytes [2]. Activation of FGFR4 leads to
activation of downstream signaling pathways and results in
suppression of gene transcription of Cyp7a1 gene that encodes
cholesterol 7a-hydroxylase, the rate-limiting enzyme for bile acid
synthesis in the liver [3,4]. Therefore, Fgf15/FGF19 plays a
critical role in regulating cholesterol and bile acid homeostasis.
Over-expression of FGF19 in FGF19-transgenic mice results in
liver tumor formation, increased energy expenditure, decreased
adiposity, and resistance to weight gain in response to a high fat
diet [5,6]. Similar effects have also been observed in mice treated
intravenously with recombinant FGF19 [7], suggesting that
Fgf15/FGF19 are important to physiology, in addition to
regulating bile acid homeostasis. The study of Fgf15 function in
mice can be a valuable research tool because mouse models are
widely used to study human physiology and pathology. Previously,
Fgf15 protein has been produced by adenoviral infection of
mammalian cells [1]. However, in order to produce large
quantities of biologically active Fgf15 protein to study its effects
in vivo, it will be ideal to develop a prokaryotic system to produce
biologically active Fgf15 protein.
The E. coli system is a popular and well characterized pro-
karyotic host system for heterologous protein expression. This
system produces large quantities of protein in a shorter period of
time and at lower cost. However, the high yield of heterologous
protein in E. coli often leads to improper protein folding, which
results in insoluble and non-functional proteins that are aggregated
in inclusion bodies [8,9]. Even though aggregation of recombinant
protein in inclusion bodies provides an easy method for protein
isolation and purification, refolding of the recombinant protein in
vitro to gain biological activity often presents great challenges [10].
Extensive efforts have been made to promote the expression of
soluble recombinant proteins in E. coli. One strategy is to reduce
protein synthesis rate by lowering incubation temperature and
inducing pressure [11]. Another widely adapted strategy to
improve the solubility of recombinant proteins is to add a fusion
tag such as glutathione-s-transferase (GST) [12,13], maltose
binding protein (MBP) [14,15], NusA [16], thioredoxin (Trx)
[12,17], or small ubiquitin-like modifier (SUMO) [18,19] to the
target protein. Fusion tags have been shown to improve protein
solubility as well as protein expression level in the E. coli system.
However, the formation of inclusion bodies in E. coli is
complicated and the mechanism for this formation is not yet
clear. For example, when using E. coli as a protein expression
system, some eukaryotic proteins are highly likely to aggre-
gate, regardless of the type of fusion tag used to improve pro-
tein solubility. This aggregation can lead to cumbersome and
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produced in the prokaryotic system is highly insoluble, the only
option to make it soluble is to use a low-yield eukaryotic expression
system. However, the low-yield protein will make the downstream
protein purification more difficult.
SUMO is a ubiquitin-related protein and regulates the activity
of a wide variety of cellular target proteins by covalent mo-
dification of the target protein’s lysine residues [20]. In the last
decade, SUMO protein has been successfully developed as a
robust prokaryotic protein expression system. Previous researches
show that SUMO improves protein expression levels and solubility
when it is fused to a protein’s N-terminus by inherited chaperone
properties, thus making SUMO a useful tag for improving
heterologous protein expression in prokaryotic cells [18,19].
In the current study, SUMO fusion tag was attached to the N-
terminus of Fgf15 and the fusion proteins were expressed in E. coli.
In this system, Fgf15 was still expressed in the form of inclusion
bodies, but the Fgf15 protein was properly refolded after dialysis
refolding steps with the assistance of fusion moiety SUMO. By
using this protocol, we were able to produce and purify biolo-
gically active Fgf15 protein in large quantity.
Materials and Methods
Ethics Statement
Mice were bred and maintained in the Laboratory of Animal
Research facility at the University of Kansas Medical Center.
Mice were housed in rooms under a standard 12-hr light/dark
cycle with access to chow and water ad libitum. All protocols and
procedures were approved by the Laboratory of Animal Research
Committee at the University of Kansas Medical Center and are in
accordance with the NIH and AALAC Guidelines (proto-
col# 2007-1699). All experiments were performed with age-
matched 10–16 week old male mice.
Plasmid construction
Yeast (S. cerevisiae) SUMO and the C-terminal protease domain
of Ulp1 (ScUlp1) were PCR amplified from yeast genomic DNA
using Phusion High-Fidelity DNA Polymerase (NEB) by primers:
ScUlp1_F: CGCGGGATCCAAACTTGTTCCTGAATTAAA-
TG, ScUlp1_R: GACTCTCGAGTTATTTTAAAGCGTCG-
GTTAAAATC, SUMO_F: CGCGGATCCATGTCGGACT-
CAGAAGTCAATC, SUMO_R: CGCAAGCTTACCACCAAT-
CTGTTCTCTGTG. The Fgf15 gene was amplified from mouse
intestinal total cDNA using the primers Fgf15_F: CGCAAGCT-
TATGGCGAGAAAGTGGAACGG and Fgf15_R: GACTCTC-
GAGTCATTTCTGGAAGCTGGGAC. Truncated Fgf15 (tFgf15)
gene without a coding fragment for the signal peptide was amplified
using primers tFgf15_F: CGCAAGCTTCGTCCCCTGGCTCAG-
CAATC, and tFgf15_R: GACTCTCGAGTCATTTCTGGAAG-
CTGGGAC. Sequences underlined were the restriction enzyme sites
used for inserting amplified fragments into the bacterial expression
vector, pET28a(+). Two additional glycines [19,20,21] required for
ScUlp1 protease to cleave the SUMO tag were inserted between the
SUMO fusion tag and Fgf15 protein with an N-terminal His6-tag. All
plasmids used for protein expression are shown in Figure 1.
Protein expression and purification of inclusion bodies
The BL21 (DE3) E. coli strain (Novagen) was transformed with
plasmid constructs. A single-colony transformant was inoculated
into 5 ml Luria Bertani (LB) medium containing 50 mg/ml
kanamycin and grown overnight at 37uC. The culture was
transferred the following day to 200 ml fresh LB medium with
kanamycin and was allowed to grow at 37uC until the optical
density (OD600) reached about 0.6. Isopropylthiogalactoside
(IPTG) was then added to a final concentration of 0.3 mM to
induce protein expression at 30uC for 4 hrs. The cells were
harvested by centrifugation at 8,000 g for 10 mins and resus-
pended in lysis buffer (50 mM Tris-HCl, pH 8.5, 0.5 mM EDTA
and 300 mM NaCl). Lysozyme (0.5 mg/ml, Sigma) and DNA
nucleases (5 units/ml, Fermentas) were added to the suspension,
and the suspension was left at room temperature for 30 mins to
lyse the cells. Ultrasonication was then performed for further cell
disruption. After sonication, the suspension was centrifuged at
10,000 g for 30 mins at 4uC. The resulting supernatant repre-
senting the soluble protein fraction and the pellet were applied to
12% or 15% SDS-PAGE gels to check the recombinant protein
expression and solubility.
Figure 1. Schematic of expression vectors. pET28a(+) vector backbone has been used to construct the expression vectors. His6-tag has been
attached to the N-terminus of the target protein, and the stop codon, TGA, has been added in front of the XhoI restriction enzyme site. Two glycine
amino acids have been introduced to the C-terminus of SUMO protein, which is required for the ScUlp1 cleavage. SP, signal peptide.
doi:10.1371/journal.pone.0020307.g001
SUMO Tag Assist FGF15 Protein In Vitro Refolding
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e20307Inclusion bodies were separated from the soluble fraction by
centrifugation at 8,000 g. Impurities trapped within the inclusion
body pellet were removed using a series of detergent and buffer
washes. After centrifugation, the pellet was washed twice with lysis
buffer containing 2 M Urea and 1% Triton X-100, followed by
two more washes with lysis buffer containing 2 M Urea, and
samples were stired for 30 mins at each step. After washing, the
precipitated inclusion bodies were solubilized with IB solubiliza-
tion buffer (20 mM Tris-HCl, pH 8.5, 8 M urea, 0.3 M NaCl,
20 mM imidazole). After incubation at room temperature for
2 hrs, the solution was centrifuged at 20,000 g for 15 mins to
remove precipitated proteins. The supernatant was processed for
protein purification by binding to a Ni-NTA resin, which was pre-
equilibrated with IB solubilization buffer. After binding at 4uC
overnight, the Ni-NTA resin was collected by low centrifugation at
1,500 g and washed twice with 50 ml IB solublization buffer.
Finally, the bound protein was eluted with 20 ml IB elution buffer
(IB solubilization buffer containing 200 mM imidazole) before
proceeding with the in-vitro refolding process.
In vitro refolding of Fgf15 by dialysis
Protein concentration of the purified inclusion bodies was
quantified by Bradford protein assay (Bio-Rad) and adjusted to
1 mg/mL using IB refolding buffer (20 mM Tris-HCl, pH 8.5,
0.3 M NaCl, 1 mM EDTA) with 8 M urea. A final concentration
of 5 mM glutathione/0.5 mM oxidized glutathione was added to
the solution and gently stirred overnight to reduce the protein.
20 ml of the reduced protein solution was then dialyzed against
1,000 ml IB refolding buffer containing 6, 3 and 2 M urea to
gradually remove urea at 4uC over the next 24 hrs. 5 mM DTT
was also included in this stage. After removal of urea denaturant,
the protein was further dialyzed against IB refolding buffer with a
stepwise reducing concentration of DTT from 5, 2 and 1 mM to
allow for disulfide bond reshuffling and oxidation in the next
48 hrs. The folded protein was then dialyzed against PBS buffer
for 24 hrs, and the PBS buffer was changed three times during this
process. Finally, the protein was centrifuged at 20,000 g for
20 mins at 4uC to remove unfolded or aggregated proteins.
Concentration of the refolded protein was determined by BCA
protein assay (Pierce).
Expression of ScUlp1 and cleavage of SUMOtFgf15 fusion
protein
The procedure for expression and purification of ScUlp1
protease is similar to what has been described above with minor
modification to buffers. 10 mM 2-mercaptoethanol was added to
all buffers to preserve enzyme activity. ScUlp1 is expressed in E.
coli cytoplasm in a soluble form, so the supernatant fraction after
lysis and centrifugation was used to bind to the Ni-NTA agarose
overnight. The binding protein was washed twice the following
day and then eluted with 10 ml elution buffer containing 200 mM
imidazole. The eluted ScUlp1 protein was dialyzed overnight
against 2 L of storage buffer (20 mM Tris-HCl, pH 8.0, 0.3 M
NaCl, 10 mM 2-mercaptoethanol) with changing the buffer twice.
Glycerol was added to a final concentration of 50% and the
purified protein was stored at 280uC. In order to determine the
purified ScUlp1 enzyme activity, commercial available SUMO tag
protease was compared in parallel, and there was no obvious
difference in activity between our protease and the commercial
protease (data not shown).
The refolded proteins were incubated with ScUlp1 protease at a
1:1000 (w/w) ratio for 1 hr at room temperature or overnight at
4uC to remove the N-terminal SUMO tag linked to the tFgf15
(His6-SUMOtFgf15) protein. After centrifugation at 15,000 g, the
mixture was passed through Hi-Trap Chelating HP columns
(Amersham Biosciences) in buffer (20 mM Tris-HCl, pH 8.0,
0.2 M NaCl) to remove the His6-SUMO tag, and recombinant
protein tFgf15 was recovered in the flow-through fractions.
Western blot was performed on these samples using a monoclonal
anti-His tag antibody (Genescript).
Activity assay of the recombinant protein tFgf15
Possible residual endotoxin in the recombinant tFgf15 was
removed by a Detoxi-Gel Endotoxin Removing Column (Pierce),
and the endotoxin concentration in the protein was determined by
a GenScript kit. There was no difference between the recombinant
protein solution and the control saline solution. Protein concen-
tration was adjusted with saline according to the dose and injection
volume of 60 ml per 30 g mouse body-weight. For a dose-
dependent experiment, C57BL/6 (n=3) wild-type (WT) mice,
were administered different amounts of tFgf15 protein through
tail-vein injection, and their livers were collected 2 hrs after
injection. Total RNA from the livers was isolated using the Trizol
method (Ambion), and reverse-transcribed to cDNA using MMLV
reverse transcriptase (Invitrogen) according to the manufacture’s
protocol. The mRNA expression of Cyp7a1 was quantified by the
Sybr-green-based real-time quantitative-PCR (qPCR) method on
the ABI 7900HT system using the primers, mCyp7a1_F: 59-
AACAACCTGCCAGTACTAGATAGC-39, and mCyp7a1_R:
59-GTGTAGAGTGAAGTCCTCCTTAGC-39. The expression
of b-actin was determined as an internal normalization control
with primers, mbActin_F: 59-GCGTGACATCAAAGAGAAGC-
39, and mbActin_R: 59-CTCGTTGCCAATAGTGATGAC-39.
Statistical analysis
All experimental data are expressed as the mean 6 SE. Multiple
groups were tested using one-way ANOVA followed by Dunnett’s
test to determine which groups were significantly different from
the control group. A P value of ,0.05 was considered to be
statistically significant.
Results
Fgf15 signal peptide affected the protein expression in E.
coli
The full length cDNA of Fgf15, including the predicted N-
terminal signal peptide, was cloned from mouse intestine and
inserted into a pET28a(+) plasmid to construct pET/Fgf15. Fgf15
contains 218 aa with a predicted 25-aa signal peptide and
produces a 25 kDa protein if the full-length protein is expressed.
Fgf15 clones were characterized for their expression and solubility
in E. coli by SDS-PAGE. Figure 2 shows proteins in lysed cell
supernatant and pellet (lanes 3 and 4, respectively). There was no
major band at the expected molecular weight in either the
supernatant or pellet fraction compared to the control E. coli lysate
(lanes 1 and 2). A more sensitive western blot analysis was then
used to detect Fgf15 expression by His-tag specific antibody, but
Fgf15 protein was not detected (data not shown).
The truncated Fgf15 (tFgf15, with molecular weight of 23 kDa)
with deletion of the signal peptide was expressed in E. coli. The
expression and solubility of tFgf15 was determined by SDS-PAGE
(Figure 2, lanes 5 and 6). Despite high expression levels, there was
no protein, at the 23 kDa size, detected in the soluble fraction
compared to cell lysate from the empty vector. These results
indicate that tFgf15 proteins were expressed at high levels in the
form of inclusion bodies. Various conditions were used to optimize
culture conditions, including decreasing the incubation tempera-
ture (from 25uCt o1 5 uC) and IPTG concentrations (from 1 mM
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improved, indicating that Fgf15 protein has a high tendency to
aggregate when expressed in E. coli. These results demonstrate that
the signal peptide in Fgf15 protein may have disturbed the
expression of Fgf15 protein in E. coli.
SUMO tag cannot improve the solubility of tFgf15
The truncated Fgf15 protein was expressed in an insoluble form
and was therefore retained in the inclusion bodies. We have
performed pilot experiments in an attempt to fuse tFgf15 with
GST and Trx, two well-known solubility enhancers, to improve
the solubility of Fgf15 protein. However, neither of these tags
enhanced Fgf15 protein solubility, even at various culture
conditions (data not shown). The SUMO tag has been shown to
improve expression levels and solubility, as well as to promote
proper folding of many proteins that are difficult to be solubilizied.
Therefore, the SUMO tag has been suggested to better enhance
solubility than GST, Trx, or MBP tags. We expressed constructs of
SUMO and SUMOtFgf15 in E. coli (Figure 3) and found that
most SUMO tags were expressed in the soluble form (lane 2) with
less SUMO tag expressed in the insoluble fraction (lane 3). Note
that SUMO migrated on the SDS-PAGE gel as more than 20 kDa
in size even though it has a molecular mass of 11.5 kDa [18].
Figure 3 shows that an apparent band of 40 kDa was observed
(lane 4, consistent with the calculated molecular mass of
recombinant SUMOtFgf15), but there was no obvious SU-
MOtFgf15 protein expression in the supernatant (lane 5). In
addition, all fusion proteins were expressed in the centrifuged
pellet fraction, which indicates that all SUMOtFgf15 proteins
expressed were insoluble and retained within inclusion bodies.
Therefore, the fusion tag SUMO could not improve tFgf15
protein solubility. These results were further confirmed by western
blot analysis against the His-tag (data not shown).
Although various highly soluble proteins have been applied as
fusion partners to enhance the solubility of recombinant Fgf15
protein, they do not improve solubility when Fgf15 is expressed
in E. coli.T h e r e f o r e ,in-vitro refolding is required to obtain
biologically active Fgf15 protein when it is expressed in a
prokaryotic system.
SUMO tag assists in the refolding of Fgf15 in vitro
Fusion proteins of SUMOtFgf15 were extracted from
inclusion bodies under denaturing conditions and were purified
by Ni-NTA chelating affinity chromatography (Qiagen) before
renatured to native state. The purification profile of SU-
MOtFgf15 is shown in Figure 4A. The majority of the fusion
protein bound to the Ni-NTA resin, leaving a small amount of
the SUMOtFgf15 in solution (lane 3). The SUMOtFgf15
protein was eluted by 200 mM imidazole and purification was
efficient as shown by the distinct band in lane 4. After
purification, the Fgf15 protein was refolded by stepwise dialysis
in the presence of reducing agents to allow for the formation of
two native disulfide bridges in the protein. The fusion protein
SUMOtFgf15 became soluble after removal of denaturants and
reducing reagents by dialysis against PBS buffer (Figure 4A,
lane 5). Refolding of the purified tFgf15 protein without the
SUMO fusion tag was also performed in parallel to compare the
effect of SUMO tag on refolding. All tFgf15 protein without
SUMO tag precipitated out after removal of denaturing reagent
(data not shown). These results suggest that SUMO moiety
f u n c t i o n sa sac h a p e r o n et oa s s i s ti t sf u s i o np a r t n e r si nr e f o l d i n g
into correct structure.
The success of refolding was also confirmed by protease ScUlp1
cleavage (Figure 4B). ScUlp1 recognizes the tertiary structure of
SUMO protein and not just the protease recognition sites [19,21],
which can be used as a method to analyze protein structure. The
amino-terminal SUMO moiety and recombinant protein tFgf15
was released from the fusion protein SUMOtFgf15 (Figure 4B,
lane 3), indicating that at least the SUMO moiety was properly
refolded.
The C-terminal of ScUlp1 was expressed at high levels in E.
coli (Figure 4C, lane 3 and 4). Approximately 30% of the total
fusion protein expressed was in soluble form. The soluble protein
lysate (Figure 4C, lane 3) was used for purification of ScUlp1
with Ni-NTA affinity chromatography under reducing condi-
tions. Most soluble proteins were bound to the Ni-NTA resin
through the N-terminus His tag. The bound ScUlp1 was eluted
by elution buffer containing 100 mM (lane 6) and 200 mM
imidazole (lane 7).
Figure 3. Expression of SUMOtFgf15 in E. coli. The solubility of
fusion proteins was analyzed on 12% SDS-PAGE gel and stained with
Coomassie Brilliant blue. M: protein molecular weight marker, lane 1:
total cellular lysate from E. coli containing pET/SUMO, lane 2: soluble
lysate fraction from E. coli containing pET/SUMO, lane 3: insoluble lysate
fraction from E. coli containing pET/SUMO, lane 4: total cellular lysate
from E. coli containing pET/SUMOtFgf15, lane 5: soluble lysate fraction
from E. coli containing pET/SUMOtFgf15, lane 6: insoluble lysate fraction
from E. coli containing pET/SUMOtFgf15.
doi:10.1371/journal.pone.0020307.g003
Figure 2. Expression of Fgf15 with or without N-terminal signal
peptide in E. coli. M: protein molecular weight marker, lane 1: soluble
lysate fraction from E. coli containing pET28a(+), lane 2: insoluble lysate
fraction from E. coli containing pET28a(+), lane 3: soluble lysate fraction
from E. coli containing pET/Fgf15, lane 4: insoluble lysate fraction from
E. coli containing pET/Fgf15, lane 5: soluble lysate fraction from E. coli
containing pET/tFgf15, lane 6: insoluble lysate fraction from E. coli
containing pET/tFgf15.
doi:10.1371/journal.pone.0020307.g002
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Many biological and biomedical applications require protein
fusion tag removal from the target protein because the tag may
alter the biological activity of the target protein. There is a Gly-Gly
motif between SUMO and tFgf15 that can be specifically
recognized and cleaved by ScUlp1. Figure 5A shows the protein
analysis by SDS-PAGE gel after protease cleavage. Fusion protein
identity was also assessed by western blot analysis using an
antibody against the His tag (Figure 5B).
The refolded SUMOtFgf15 protein (lane 2) was effectively
cleaved by ScUlp1, and two new bands corresponding to the
expected molecular weights, approximately 25 kDa for SUMO
and 22 kDa for tFgf15, were detected (lane 3). After applying the
cleaved sample to the Ni-NTA column, the N-terminally His6-
tagged fusion proteins, including SUMOtFgf15 (non-cleaved),
SUMO moiety (cleaved) and protease ScUlp1, bound to the
column. The untagged Fgf15 protein did not bind to the column
and remained in flow-through solution (lane 4). Coomassie blue
staining revealed only one band without any contaminant
(Figure 5A, lane 4). Therefore the purity of tFgf15 protein was
estimated to be greater than 90%. The His-tagged protein that
bound to the column was also eluted by imidazole to confirm the
identity of the binding proteins (lane 5).
The SUMO tag was removed by ScUlp1 cleavage, which
requires reducing buffer conditions containing 2-mercaptoethanol
or DTT. However, the reducing regents also broke disulfide bonds
in the properly refolded tFgf15 protein. This problem was solved
by using an increased amount of ScUlp1 protease for a longer
incubation time. The extended overnight incubation without
reducing reagents resulted in more than 90% cleavage of the
fusion protein (Figure 5, lane 3).
Typically, the expression level of SUMOtFgf15 protein in the
BL21(DE3) strain was about 10% of the total E. coli protein.
Around 200 mg of purified SUMOtFgf15 inclusion bodies could be
obtained from 1 liter of bacteria culture media. All proteins were
kept soluble after removal of urea through dialysis in the refolding
step. However, during the cleavage step, there was some protein
precipitation observed by an increase in solution turbidity, which
indicates some fusion protein failed to properly refold and thus was
precipitated after the SUMO fusion tag was cleaved. At the end of
the purification process, we could obtain about 6 mg of purified
Fgf15 protein from 1 liter of media, thus the yield of correctly
refolded tFgf15 protein from inclusion bodies is about 3%.
Figure 4. Purification of SUMOtFgf15 inclusion bodies (A), confirmation of SUMOtFgf15 protein refolding following ScUlp1
digestion (B). Panel A lane 1: soluble cell lysate from pET/SUMOtFgf15, lane 2: insoluble inclusion bodies, lane 3: unbound protein after Ni-NTA
resin, lane 4: elutes from Ni-NTA by 200 mM imidazole, lane 5: soluble protein after refolding. Panel B lane 1: purified SUMOtFgf15 for starting
refolding, lane 2: soluble SUMOtFgf15 protein after refolding, lane 3: refolded SUMOtFgf15 digested by ScUlp1 for 30 mins. Panel C shows the
expression and purification of protease ScUlp1. Lane 1–2: lysate from E. coli containing pET28a(+) (lane 1, soluble fraction, lane 2: insoluble fraction),
lane3–4: lysate from E. coli containing pET/ScUlp1 (lane 3: soluble fraction, lane 4: insoluble fraction), lane 5: unbound protein after Ni-NTA resin, lane
6: eluted ScUlp1 by 100 mM imidazole, lane 7: eluted ScUlp1 by 200 mM imidazole.
doi:10.1371/journal.pone.0020307.g004
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active in vivo
Fgf15 is known to reduce the mRNA expression of the Cyp7a1
gene in liver. To assess the biological activity of the recombinant
Fgf15 protein in vivo, we analyzed the effect of Fgf15 on Cyp7a1
gene expression. Mice were administered SUMOtFgf15 or tFgf15
protein through tail-vein injection. Both SUMOtFgf15 and tFgf15
protein suppressed 90% of hepatic Cyp7a1 mRNA levels, and
there was no difference in the extent of suppression between
SUMOtFgf15 and tFgf15 protein (Figure 6A). In addition,
SUMO protein alone did not suppress Cyp7a1 expression,
indicating that the biological activity of the SUMOtFgf15 fusion
protein comes from the tFgf15 protein and not the SUMO moiety.
These results, in combination with those from Figure 4B, suggest
that both the SUMO moiety and tFgf15 protein have kept their
individual structures after refolding in vitro. With the assistance of
SUMO fusion tag, tFgf15 was properly refolded and maintained
its function, and assumedly has kept its tertiary structure after
cleavage of the fusion tag.
Biological activity of the recombinant tFgf15 protein was further
confirmed in mice (Figure 6B). Increasing amounts of recombi-
nant tFgf15 were injected through tail vein into WT mice. Hepatic
Cyp7a1 mRNA levels decreased with increasing tFgf15 dosage,
indicating that tFgf15 suppresses Cyp7a1 gene transcription in a
dose-dependent manner. In detail, as low as 5 mg per kg body
weight dosage of recombinant tFgf15 significantly suppressed
Cyp7a1 gene expression. These data further indicated that the
recombinant tFgf15 protein was biologically active.
Discussion
The E. coli expression system is a fast, inexpensive and widely
used system for heteroprotein production. However, this system
lacks post-translational modifications, making it an unsuitable
system for expressing proteins that require post-translational
modifications for their biological activity. Fgf15/FGF19 does not
contain potential N-linked glycosylation sites [4,22,23], indicating
that it does not require post-translational modification, therefore we
may use the E. coli expressionsystem to express Fgf15 proteinin vitro.
However,therearefivecysteines inthe Fgf15/FGF19peptidechain
that form two putative disulfide bonds in the protein molecule with
one of the two disulfide bonds being conserved throughout the FGF
family [4,22]. It’s well known that disulfide bonds are important for
Figure 6. Biological activity of the recombinant Fgf15 proteins. (A) Hepatic Cyp7a1 mRNA levels in mice injected intravenously with saline,
fusion protein SUMOtFgf15, or tFgf15 without SUMO fusion tag. (B) Dose-dependency in suppressing hepatic Cyp7a1 gene expression in mice by
recombinant tFgf15. * P,0.05, compared to saline-treated group.
doi:10.1371/journal.pone.0020307.g006
Figure 5. SUMOtFgf15 cleavage and tFgf15 purification by Ni-NTA resin. The samples were separated on 15% SDS-PAGE gel, and stained
with Coomassie Brilliant Blue (A) or undergone western blot analysis (B) with anti-His6 tag antibody. M: protein molecular weight marker, lane 1:
purified SUMOtFgf15 inclusion bodies, Lane 2: refolded SUMOtFgf15, lane 3: SUMOtFgf15 digested by ScUlp1, lane 4: purified tFgf15 flow through Ni-
NTA column, lane 5: eluate from Ni-NTA column using 200 mM imidazle.
doi:10.1371/journal.pone.0020307.g005
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It is also known that the reducing environment inE. coli cytoplasmis
unfavorable for disulfide bond formation. Previous research on the
crystal structureofFGF19protein[4,23], whichrequiredisolationof
the protein from inclusion bodies followed by subsequent in-vitro
refolding, suggests that Fgf15, as well as FGF19, may be prone to
form inclusion bodies when expressed in E. coli. Indeed, the pilot
experiments for optimization of E. coli culture conditions and fusion
expression with various tags such as GST, Trx, and SUMO did not
show improvement for increasing Fgf15 protein solubility, indicat-
ing that a crucial factor has been missing during Fgf15 refolding,
which results in retaining of Fgf15 in the inclusion bodies.
Fgf15 shows a high tendency to be expressed in insoluble form,
therefore, in-vitro refolding is required to recover bioactive proteins.
Protein refolding is not only complicated and time-consuming, but
also the mechanism for refolding is still unclear. Therefore,
successful refolding of proteins is not guaranteed. It’s believed that
there are many intermediates formed during the protein refolding
process, and refolding and aggregation appear to occur in parallel.
Nonetheless aggregation-prone intermediates form early in the
protein folding process. Therefore, proper protein refolding
depends on a competition between correct folding and aggregation.
In many cases, formation of the correct disulfide bond is a rate-
limiting step during the refolding process and incorrect disulfide
bond formation leads to protein precipitation. To prevent
aggregation, many small chemical compounds, such as L-arginine,
have been used successfully to prevent protein aggregation and to
enhance correct protein folding [9]. However, there is no report of
protein fusion tags for enhancing in-vitro refolding.
SUMO protein has been shown to markedly enhance the
expression and solubility of its fusion proteins, and the mechanism
in part lies in the structure of SUMO protein which contains an
external hydrophilic surface and inner hydrophobic core [18,19].
This structure may exert a detergent-like effect on its linked
proteins, which may possess robust folding characteristics,
resulting in refolding of SUMO faster in the fusion protein during
the refolding process. Folded SUMO may function as a general
molecular chaperone to prevent aggregation of intermediates,
therefore keeping folding intermediates in solution long enough to
adopt correct conformations [9,10,24,25]. According to this
theory, a two-step dialysis was used to refold the SUMOtFgf15
protein. First, denaturing reagents were removed stepwise to make
the protein form a tight conformation in the presence of reducing
reagents that were used to prevent formation of improper disulfide
bonds. Second, oxidation was introduced to form disulfide bonds
to maintain the correct structure of proteins. Even though the
mechanism is not elucidated, it is clear that SUMO tag assists the
fused Fgf15 protein to recover from misfolding inclusion bodies.
The recovered proteins have strong biological activities, indicating
that Fgf15 has gained proper conformation after refolding.
It is well known that inclusion bodies can simplify the protein
isolation process. However, proper protein refolding after
inclusion body isolation is a great challenge [9,10]. We have
demonstrated that SUMO is a potential solution to this problem
because it promotes in-vitro refolding by helping its partner protein
to quickly fold in its correct conformation. In addition, SUMO has
solubility-enhancing characteristics. In conclusion, the use of
fusion partner SUMO is an effective system for heterologous
protein expression. In combination with the easy isolation and
purification of inclusion bodies, SUMO offers the advantage of
effective in-vitro refolding of its partner proteins and can greatly
accelerate the recombinant protein production.
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